Crohn's & colitis 360 · 2026
Incidence and prevalence of immune-mediated extraintestinal manifestations in pediatric inflammatory bowel disease: a systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Colman Ruben J, Vuyyuru Sudheer K, Solitano Virginia, MacDonald John K, Le Jessica, Ricciuto Amanda, Berard Roberta, Mohammed Javed A, Ma Christopher, Jairath Vipul, Crowley Eileen
Аннотация
BACKGROUND: Immune-mediated extraintestinal manifestations (IM-EIMs) are common in pediatric inflammatory bowel disease (pIBD). This systematic review and meta-analysis aimed to summarize the incidence and prevalence of IM-EIMs in pIBD.
METHODS: MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov were searched up to May 6, 2024, for studies that included pIBD (2-17 years) patients diagnosed with IM-EIMs. Primary outcomes included the incidence and prevalence of IM-EIMs among pIBD. Meta-analysis included pooled proportions of IM-EIMs using DerSimonian-Laird random-effects model.
RESULTS: The pooled proportion of IM-EIMs overall was 10% (95% CI, 8%-12%; I2 = 97.2%) among 65 pIBD studies (35 343 patients). The pooled proportion of IM-EIMs was 10% (95% CI, 7%-13%; I2 = 94.8%) among 37 Crohn's disease (CD) studies (7657 patients), compared to 11% (95% CI, 7%-15%; I2 = 93.3%) among 39 ulcerative colitis (UC) studies (4698 patients). Enthesitis was the highest reported individual IM-EIM (23%, 95% CI, 4%-50%; I2 = 94.7%) in pIBD. Arthritis was the second highest reported individual IM-EIM (8%, 95% CI, 6%-10%; I2 = 96%) in pIBD, followed by primary sclerosing cholangitis (PSC) in UC (5%, 95% CI, 4%-7%; I2 = 81%). Uveitis, pyoderma gangrenosum, autoimmune hepatitis, and PSC in CD were the lowest reported IM-EIMs at 1% or less. The largest difference in proportions between IBD phenotypes was PSC, which was 4% higher in UC than CD.
CONCLUSIONS: While musculoskeletal manifestations are common, fewer than 5% of pIBD patients experience ophthalmological, dermatological, and liver IM-EIMs. The small number of studies resulted in significant methodological and statistical heterogeneity. Multicenter collaborative efforts are needed to systematically describe the epidemiology of IM-EIMs in pIBD.
METHODS: MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov were searched up to May 6, 2024, for studies that included pIBD (2-17 years) patients diagnosed with IM-EIMs. Primary outcomes included the incidence and prevalence of IM-EIMs among pIBD. Meta-analysis included pooled proportions of IM-EIMs using DerSimonian-Laird random-effects model.
RESULTS: The pooled proportion of IM-EIMs overall was 10% (95% CI, 8%-12%; I2 = 97.2%) among 65 pIBD studies (35 343 patients). The pooled proportion of IM-EIMs was 10% (95% CI, 7%-13%; I2 = 94.8%) among 37 Crohn's disease (CD) studies (7657 patients), compared to 11% (95% CI, 7%-15%; I2 = 93.3%) among 39 ulcerative colitis (UC) studies (4698 patients). Enthesitis was the highest reported individual IM-EIM (23%, 95% CI, 4%-50%; I2 = 94.7%) in pIBD. Arthritis was the second highest reported individual IM-EIM (8%, 95% CI, 6%-10%; I2 = 96%) in pIBD, followed by primary sclerosing cholangitis (PSC) in UC (5%, 95% CI, 4%-7%; I2 = 81%). Uveitis, pyoderma gangrenosum, autoimmune hepatitis, and PSC in CD were the lowest reported IM-EIMs at 1% or less. The largest difference in proportions between IBD phenotypes was PSC, which was 4% higher in UC than CD.
CONCLUSIONS: While musculoskeletal manifestations are common, fewer than 5% of pIBD patients experience ophthalmological, dermatological, and liver IM-EIMs. The small number of studies resulted in significant methodological and statistical heterogeneity. Multicenter collaborative efforts are needed to systematically describe the epidemiology of IM-EIMs in pIBD.